Effect of the lipoxygenase inhibitor baicalein on bone tissue and bone healing in ovariectomized rats.
Baicalein
Biomechanics
Fracture healing
Lipoxygenase inhibitor
Osteoporosis
Journal
Nutrition & metabolism
ISSN: 1743-7075
Titre abrégé: Nutr Metab (Lond)
Pays: England
ID NLM: 101231644
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
10
2018
accepted:
10
12
2018
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
18
1
2019
Statut:
epublish
Résumé
Osteoporosis is one of the world's major medical burdens in the twenty-first century. Pharmaceutical intervention currently focusses on decelerating bone loss, but phytochemicals such as baicalein, which is a lipoxygenase inhibitor, may rescue bone loss. Studies evaluating the effect of baicalein in vivo are rare. We administered baicalein to sixty-one three-month-old female Sprague-Dawley rats. They were divided into five groups, four of which were ovariectomized (OVX) and one non-ovariectomized (NON-OVX). Eight weeks after ovariectomy, bilateral tibial osteotomy with plate osteosynthesis was performed and bone formation quantified. Baicalein was administered subcutaneously using three doses (C1: 1 mg/kg BW; C2: 10 mg/kg BW; and C3: 100 mg/kg BW) eight weeks after ovariectomy for four weeks. Finally, femora and tibiae were collected. Biomechanical tests, micro-CT, ashing, histological and gene expression analyses were performed. Biomechanical properties were unchanged in tibiae and reduced in femora. In tibiae, C1 treatment enhanced callus density and cortical width and decreased callus area. In the C3 group, callus formation was reduced during the first 3 weeks after osteotomy, correlating to a higher mRNA expression of Baicalein enhanced callus density and cortical width but impaired early callus formation in tibiae. In femora, it diminished the biomechanical properties and calcium-to-phosphate ratio. Thus, it is not advisable to apply baicalein to treat early bone fractures. To determine the exact effects on bone healing, further studies in which baicalein treatments are started at different stages of healing are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Osteoporosis is one of the world's major medical burdens in the twenty-first century. Pharmaceutical intervention currently focusses on decelerating bone loss, but phytochemicals such as baicalein, which is a lipoxygenase inhibitor, may rescue bone loss. Studies evaluating the effect of baicalein in vivo are rare.
METHODS
METHODS
We administered baicalein to sixty-one three-month-old female Sprague-Dawley rats. They were divided into five groups, four of which were ovariectomized (OVX) and one non-ovariectomized (NON-OVX). Eight weeks after ovariectomy, bilateral tibial osteotomy with plate osteosynthesis was performed and bone formation quantified. Baicalein was administered subcutaneously using three doses (C1: 1 mg/kg BW; C2: 10 mg/kg BW; and C3: 100 mg/kg BW) eight weeks after ovariectomy for four weeks. Finally, femora and tibiae were collected. Biomechanical tests, micro-CT, ashing, histological and gene expression analyses were performed.
RESULTS
RESULTS
Biomechanical properties were unchanged in tibiae and reduced in femora. In tibiae, C1 treatment enhanced callus density and cortical width and decreased callus area. In the C3 group, callus formation was reduced during the first 3 weeks after osteotomy, correlating to a higher mRNA expression of
CONCLUSIONS
CONCLUSIONS
Baicalein enhanced callus density and cortical width but impaired early callus formation in tibiae. In femora, it diminished the biomechanical properties and calcium-to-phosphate ratio. Thus, it is not advisable to apply baicalein to treat early bone fractures. To determine the exact effects on bone healing, further studies in which baicalein treatments are started at different stages of healing are needed.
Identifiants
pubmed: 30651746
doi: 10.1186/s12986-018-0327-2
pii: 327
pmc: PMC6329162
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Déclaration de conflit d'intérêts
The local ethics committee permitted the experiment (application number G14/1530).Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Tissue Eng Part B Rev. 2010 Apr;16(2):209-17
pubmed: 19857045
Oncotarget. 2017 Sep 18;8(49):86098-86116
pubmed: 29156780
J Bone Miner Res. 1987 Dec;2(6):595-610
pubmed: 3455637
J Bone Miner Metab. 2015 Mar;33(2):154-60
pubmed: 24633537
J Bone Miner Res. 2010 Jul;25(7):1468-86
pubmed: 20533309
Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):10-4
pubmed: 17973900
Calcif Tissue Int. 2015 Aug;97(2):134-44
pubmed: 25894067
Clin J Am Soc Nephrol. 2008 Nov;3 Suppl 3:S131-9
pubmed: 18988698
Osteoporos Int. 2006 Dec;17(12):1726-33
pubmed: 16983459
J Bone Miner Res. 2006 Jan;21(1):89-96
pubmed: 16355277
Food Chem Toxicol. 2008 Nov;46(11):3375-82
pubmed: 18786594
J Bone Joint Surg Am. 2009 Nov;91(11):2653-65
pubmed: 19884440
PLoS Genet. 2014 Dec 04;10(12):e1004820
pubmed: 25474590
Molecules. 2018 Jan 20;23(1):
pubmed: 29361712
J Bone Miner Res. 2013 Jan;28(1):2-17
pubmed: 23197339
J Nutr Metab. 2016;2016:3703216
pubmed: 28050282
Int J Endocrinol. 2014;2014:235060
pubmed: 25147565
Injury. 2011 Jun;42(6):551-5
pubmed: 21489527
J Orthop Trauma. 2014 May;28(5):294-9
pubmed: 24296600
Int Immunopharmacol. 2014 Aug;21(2):301-8
pubmed: 24859058
J Appl Physiol (1985). 2013 Sep;115(6):892-9
pubmed: 23869068
Mol Cell Endocrinol. 2012 Oct 15;362(1-2):128-38
pubmed: 22698522
Calcif Tissue Int. 2017 Dec;101(6):553-563
pubmed: 29063963
J Ethnopharmacol. 2012 Sep 28;143(2):732-9
pubmed: 22884869
Osteoporos Int. 2010 Feb;21(2):251-61
pubmed: 19436940
Drug Des Devel Ther. 2015 Sep 09;9:5169-83
pubmed: 26392752
J Orthop Res. 2003 Nov;21(6):1011-7
pubmed: 14554213
J Cell Physiol. 2007 Sep;212(3):666-74
pubmed: 17458902
Food Chem Toxicol. 2013 Mar;53:325-33
pubmed: 23266503
J Orthop Res. 2006 Aug;24(8):1679-86
pubmed: 16788988
Int Immunopharmacol. 2016 Jul;36:118-131
pubmed: 27131574
Curr Drug Targets. 2011 Mar 1;12(3):288-301
pubmed: 20955151
AJR Am J Roentgenol. 1992 Aug;159(2):245-52
pubmed: 1632335
Langenbecks Arch Surg. 2010 Feb;395(2):163-72
pubmed: 19048282
Acta Pharmacol Sin. 2010 Feb;31(2):137-44
pubmed: 20139896
Science. 2004 Jan 9;303(5655):229-32
pubmed: 14716014
Sci Rep. 2018 May 16;8(1):7712
pubmed: 29769600
Acta Orthop. 2010 Dec;81(6):748-55
pubmed: 21067431
J Orthop Res. 2016 Jul;34(7):1206-15
pubmed: 26704186
Calcif Tissue Int. 2010 Aug;87(2):168-80
pubmed: 20532877
Calcif Tissue Int. 2018 Jul;103(1):80-94
pubmed: 29352329
Bone. 2010 Sep;47(3):480-92
pubmed: 20580683
Evid Based Complement Alternat Med. 2015;2015:973524
pubmed: 26649065
Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):209-216
pubmed: 29263736
Bioorg Med Chem. 2015 Nov 1;23(21):7069-78
pubmed: 26432605
Bone. 2002 Jul;31(1):165-72
pubmed: 12110430
J Nat Med. 2018 Jan;72(1):181-191
pubmed: 28921127
Connect Tissue Res. 2013;54(6):426-31
pubmed: 24020358
Lasers Med Sci. 2013 Nov;28(6):1467-74
pubmed: 23307440
Ann Intern Med. 2011 Aug 16;155(4):276; author reply 276-7
pubmed: 21844561
Bone. 2017 Aug;101:134-144
pubmed: 28455215
Calcif Tissue Int. 2015 Oct;97(4):391-401
pubmed: 26084691
Clin Orthop Relat Res. 1998 Oct;(355 Suppl):S132-47
pubmed: 9917634
Tumour Biol. 2015 Jun;36(6):4731-40
pubmed: 25618603
Int J Oncol. 2013 Nov;43(5):1652-8
pubmed: 24008356
J Cell Biochem. 2008 Aug 1;104(5):1906-17
pubmed: 18384125
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Clin Mol Allergy. 2007 Nov 26;5:5
pubmed: 18039391
Calcif Tissue Int. 2013 Jun;92(6):509-20
pubmed: 23416966
Calcif Tissue Int. 2010 Sep;87(3):226-35
pubmed: 20614110
Bone. 2016 May;86:119-30
pubmed: 26946132
Mol Cell Biochem. 2015 Jul;405(1-2):187-96
pubmed: 25893737
J Endocrinol. 2009 May;201(2):253-62
pubmed: 19273502
J Orthop Trauma. 2015 Dec;29 Suppl 12:S6-9
pubmed: 26584270
Mayo Clin Proc. 2015 Jan;90(1):53-62
pubmed: 25481833
Calcif Tissue Int. 2016 Oct;99(4):408-22
pubmed: 27272029
Osteoporos Int. 2014 Oct;25(10):2493-6
pubmed: 24980184
Bone Joint Res. 2013 Feb 01;2(2):41-50
pubmed: 23610701
Drug Des Devel Ther. 2016 Apr 18;10:1419-41
pubmed: 27143851
Phytother Res. 2010 Jun;24 Suppl 2:S168-74
pubmed: 20013821
Bone. 2008 Mar;42(3):491-7
pubmed: 18187376
J Neuroimmunol. 2014 Dec 15;277(1-2):50-6
pubmed: 25441240